[go: up one dir, main page]

WO2002018609A3 - Methodes de transduction cellulaire stable a l'aide de vecteurs viraux - Google Patents

Methodes de transduction cellulaire stable a l'aide de vecteurs viraux Download PDF

Info

Publication number
WO2002018609A3
WO2002018609A3 PCT/US2001/027091 US0127091W WO0218609A3 WO 2002018609 A3 WO2002018609 A3 WO 2002018609A3 US 0127091 W US0127091 W US 0127091W WO 0218609 A3 WO0218609 A3 WO 0218609A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
viral vectors
methods
transduced
cell
Prior art date
Application number
PCT/US2001/027091
Other languages
English (en)
Other versions
WO2002018609A2 (fr
WO2002018609A9 (fr
Inventor
Laurent Humeau
Wei Han
Xiaobin Lu
Vladimir Stepushkin
Mechelle Lesher
Brian Davis
Yung-Nien Chang
Boro Dropulic
Original Assignee
Virxsys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01966434A priority Critical patent/EP1315823A2/fr
Priority to BR0113619-4A priority patent/BR0113619A/pt
Priority to CA2421063A priority patent/CA2421063C/fr
Priority to NZ524642A priority patent/NZ524642A/en
Priority to MXPA03001758A priority patent/MXPA03001758A/es
Priority to JP2002522515A priority patent/JP2004528806A/ja
Priority to IL15459901A priority patent/IL154599A0/xx
Priority to KR10-2003-7002964A priority patent/KR20030074592A/ko
Application filed by Virxsys filed Critical Virxsys
Priority to AU8694701A priority patent/AU8694701A/xx
Priority to AU2001286947A priority patent/AU2001286947B2/en
Publication of WO2002018609A2 publication Critical patent/WO2002018609A2/fr
Publication of WO2002018609A3 publication Critical patent/WO2002018609A3/fr
Priority to NO20030901A priority patent/NO20030901L/no
Publication of WO2002018609A9 publication Critical patent/WO2002018609A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes, ainsi que des compositions associées, permettant d'obtenir une transduction cellulaire efficace à l'aide de vecteurs viraux. L'efficacité de la transduction augmente par la mise en contact de la cellule à transduire avec une ou plusieurs molécules de liaison à la surface de la cellule. Le contact avec la surface d'une molécule de liaison à la surface de la cellule peut se produire avant, après, ou en même temps qu'un contact entre le vecteur viral et la cellule. Les vecteurs transduits peuvent être construits pour exprimer un gène d'intérêt, permettant aux cellules transduites d'être utilisées comme agents thérapeutiques et prophylactiques.
PCT/US2001/027091 2000-08-31 2001-08-29 Methodes de transduction cellulaire stable a l'aide de vecteurs viraux WO2002018609A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL15459901A IL154599A0 (en) 2000-08-31 2001-08-29 Methods for transduction of cells with viral vectors
CA2421063A CA2421063C (fr) 2000-08-31 2001-08-29 Methodes de transduction cellulaire stable a l'aide de vecteurs viraux
NZ524642A NZ524642A (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors
MXPA03001758A MXPA03001758A (es) 2000-08-31 2001-08-29 Metodos para la transduccion estable de celulas con vectores virales.
JP2002522515A JP2004528806A (ja) 2000-08-31 2001-08-29 ウイルスベクターを用いる細胞の安定な形質導入のための方法
EP01966434A EP1315823A2 (fr) 2000-08-31 2001-08-29 Methodes de transduction cellulaire stable a l'aide de vecteurs viraux
AU2001286947A AU2001286947B2 (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors
KR10-2003-7002964A KR20030074592A (ko) 2000-08-31 2001-08-29 바이러스 벡터를 사용한 세포의 안정한 형질도입 방법
AU8694701A AU8694701A (en) 2000-08-31 2001-08-29 Methods for stable transduction of cells with viral vectors
BR0113619-4A BR0113619A (pt) 2000-08-31 2001-08-29 Métodos para a transdução estável de células com vetores virais.
NO20030901A NO20030901L (no) 2000-08-31 2003-02-26 Fremgangsmåter for stabil transduksjon av celler med virale vektorer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/653,088 US6627442B1 (en) 2000-08-31 2000-08-31 Methods for stable transduction of cells with hiv-derived viral vectors
US09/653,088 2000-08-31

Publications (3)

Publication Number Publication Date
WO2002018609A2 WO2002018609A2 (fr) 2002-03-07
WO2002018609A3 true WO2002018609A3 (fr) 2003-01-16
WO2002018609A9 WO2002018609A9 (fr) 2003-08-14

Family

ID=24619453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027091 WO2002018609A2 (fr) 2000-08-31 2001-08-29 Methodes de transduction cellulaire stable a l'aide de vecteurs viraux

Country Status (15)

Country Link
US (2) US6627442B1 (fr)
EP (2) EP2031069A1 (fr)
JP (1) JP2004528806A (fr)
KR (1) KR20030074592A (fr)
CN (1) CN100443593C (fr)
AU (2) AU8694701A (fr)
BR (1) BR0113619A (fr)
CA (1) CA2421063C (fr)
CZ (1) CZ2003569A3 (fr)
IL (1) IL154599A0 (fr)
MX (1) MXPA03001758A (fr)
NO (1) NO20030901L (fr)
NZ (1) NZ524642A (fr)
RU (1) RU2280074C2 (fr)
WO (1) WO2002018609A2 (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358061A1 (fr) * 2000-09-08 2002-03-08 Stemcell Technologies Inc. Nouvelles compositions d'anticorps pour la selection negative de sous-ensembles particuliers de leucocytes de rats
MXPA03006624A (es) * 2001-01-25 2004-11-12 Virxsys Corp Metodos y composiciones para la identificacion de la funcion de genes.
US20030121062A1 (en) * 2001-12-21 2003-06-26 Oxford Biomedica (Uk) Limited Transgenic organism
US20040002158A1 (en) * 2002-06-05 2004-01-01 Lung-Ji Chang Long term expression of lentiviral vectors
JP2006505280A (ja) * 2002-11-07 2006-02-16 チャン・ルン−ジ 改変樹状細胞
EP1599223A4 (fr) * 2003-02-04 2006-10-11 Univ Connecticut Health Ct Complexes de molecule antigene-ligand immunogene cd91 et proteines de fusion
US20040191215A1 (en) * 2003-03-25 2004-09-30 Michael Froix Compositions for induction of a therapeutic response
EP1663158A2 (fr) 2003-06-24 2006-06-07 Baxter International Inc. Methode d'administration de medicaments au cerveau
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
WO2005023313A1 (fr) * 2003-09-09 2005-03-17 Virxsys Corporation Approches a base de vecteurs de lentivirus permettant de generer une reponse immunitaire au virus de l'immunodeficience humaine
US20080038824A1 (en) * 2004-01-29 2008-02-14 National Institute Of Advanced Industrial Science And Technology Composition and Method for Elevating Gene Transfer Efficiency
AU2005255039A1 (en) 2004-06-15 2005-12-29 Baxter Healthcare S.A. Ex-vivo application of solid microparticulate therapeutic agents
US20060003452A1 (en) * 2004-07-01 2006-01-05 Virxsys Corporation Vector packaging cell line
WO2006031870A2 (fr) 2004-09-14 2006-03-23 Argos Therapeutics, Inc. Amplification de souches independantes d'agents pathogenes et vaccins les comprenant
AU2006214278C1 (en) 2005-02-16 2012-07-19 Miltenyi Biotec Technology, Inc. Lentiviral vectors and their use
WO2006113622A2 (fr) * 2005-04-15 2006-10-26 University Of Maryland, Baltimore Vaccination directe de la moelle osseuse
CA2606928A1 (fr) * 2005-05-20 2006-11-30 Virxsys Corporation Transduction de cellules primaires
US20070020238A1 (en) * 2005-06-01 2007-01-25 David Baltimore Method of targeted gene delivery using viral vectors
JP2006345852A (ja) * 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
DK2048955T3 (da) * 2006-07-21 2013-09-02 California Inst Of Techn Målrettet gen-tilførsel til dendrit-cellevaccination
BRPI0909780B1 (pt) * 2008-03-05 2022-05-03 Baxter International Inc Suspensão contendo uma partícula com superfície modificada, composição farmacêutica compreendendo a referida suspensão, método para aprimorar a absorção celular de um agente ativo, uso de partículas com superfície modificada, e método de preparação de uma partícula com superfície modificada
US9050269B2 (en) * 2009-03-10 2015-06-09 The Trustees Of The University Of Pennsylvania Protection of virus particles from phagocytosis by expression of CD47
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
EA032403B1 (ru) * 2009-07-24 2019-05-31 Иммьюн Дизайн Корп. Лентивирусные векторы, псевдотипированные гликопротеином оболочки вируса синдбис
FR2955122B1 (fr) * 2010-01-11 2012-09-28 Ct Nat De Rech Scientique Cellules endotheliales felines organospecifiques et utilisations.
WO2011119920A2 (fr) 2010-03-25 2011-09-29 Oregon Health & Science University Glycoprotéines du cmv et vecteurs recombinés
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
RU2478711C1 (ru) * 2011-12-19 2013-04-10 Открытое акционерное общество "Институт стволовых клеток человека" Способ повышения эффективности вирусной трансдукции
SG11201403445YA (en) * 2011-12-22 2014-07-30 Hoffmann La Roche Full length antibody display system for eukaryotic cells and its use
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
DK2831095T3 (en) 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
EP2679596B1 (fr) 2012-06-27 2017-04-12 International Aids Vaccine Initiative Variante de la protéine env du VIH-1
US20140037599A1 (en) * 2012-08-03 2014-02-06 The Trustees Of The University Of Pennsylvania Compositions and Methods of Treating T Cell Deficiency
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US20170218397A1 (en) * 2014-07-30 2017-08-03 Texas Tech University System Conditional cytotoxic gene therapy vector for selectable stem cell modification for anti hiv gene therapy
CN104610442B (zh) * 2015-01-30 2017-11-24 张永辉 一种细胞因子颗粒及其应用
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
RU2021103425A (ru) * 2016-02-12 2021-02-25 Блубёрд Био, Инк. Композиции, повышающие число копий вектора (чкв), и способы их применения
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
PL3445406T3 (pl) 2016-04-20 2022-02-07 Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas, O.A., M.P. Kompozycje i sposoby zwiększonej ekspresji genów PKLR
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MA46959A (fr) 2016-12-02 2019-10-09 Juno Therapeutics Inc Cellules b modifiées et compositions et méthodes associées
KR20200003160A (ko) * 2017-05-03 2020-01-08 바이오마린 파머수티컬 인크. 조혈모세포의 형질도입을 위한 개선된 렌티바이러스
EP3648776A4 (fr) 2017-07-06 2021-04-07 The Medical College of Wisconsin, Inc. Nouvelle stratégie d'enrichissement in vitro et in vivo ciblant les lymphocytes dérivés de csh transduites par un vecteur pour la thérapie de troubles
US11584908B2 (en) 2017-09-20 2023-02-21 The Charles Stark Draper Laboratory, Inc. Apparatus for efficient genetic modification of cells
CN111163810B (zh) 2017-10-16 2024-09-10 能源环境和技术研究中心O.A.,M.P. 用于递送pklr以治疗丙酮酸激酶缺乏症的慢病毒载体
TWI833719B (zh) 2017-11-17 2024-03-01 美商艾歐凡斯生物治療公司 來自細針抽吸物及小活體組織切片之腫瘤浸潤淋巴細胞（ｔｉｌ）擴增
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
CA3083118A1 (fr) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion de lymphocytes de sang peripherique (pbl) a partir de sang peripherique
EP3737743A1 (fr) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Procédés de génération de produits de til enrichis pour des lymphocytes t spécifiques d'un antigène tumoral
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (fr) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Procédés de génération de produits de til enrichis pour des lymphocytes t spécifiques d'un antigène tumoral
CN112513072A (zh) 2018-04-27 2021-03-16 威斯康星州医药大学股份有限公司 慢病毒载体转化的t-rapa细胞在改善溶酶体贮积症中的应用
MX2020011386A (es) 2018-04-27 2021-01-29 Spacecraft Seven Llc Terapia genica para la degeneracion del snc.
JP2021521846A (ja) 2018-04-27 2021-08-30 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の拡大培養及び遺伝子編集のための閉鎖型プロセス並びに免疫療法におけるその使用
CA3117459A1 (fr) 2018-10-31 2020-05-07 Mesoblast International Sarl Expansion de cellules souches hematopoietiques
EP3877511A1 (fr) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion de til utilisant des inhibiteurs de la voie akt
EP3876957B1 (fr) 2018-11-05 2025-01-22 Iovance Biotherapeutics, Inc. Lymphocytes infiltrant les tumeurs pour le traitement de patients atteints de cbnpc réfractaires aux anticorps anti-pd-1
KR20210099573A (ko) 2018-11-05 2021-08-12 이오반스 바이오테라퓨틱스, 인크. 개선된 종양 반응성 t-세포의 선택
ES3036072T3 (en) 2018-11-05 2025-09-12 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP7710372B2 (ja) 2018-12-19 2025-07-18 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
AU2020233284A1 (en) 2019-03-01 2021-09-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4048295A1 (fr) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Édition génique de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
JP7749561B2 (ja) 2019-12-11 2025-10-06 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
CN115003818A (zh) * 2020-01-22 2022-09-02 科济生物医药（上海）有限公司 病毒载体转导细胞的方法
CA3177413A1 (fr) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection de lymphocytes t reactifs a une tumeur ameliores
EP4146794A1 (fr) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
BR112023001852A2 (pt) 2020-08-07 2023-02-23 Spacecraft Seven Llc Terapia gênica com placofilina-2 (pkp2) usando vetor de aav
WO2022076606A1 (fr) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
CA3201818A1 (fr) 2020-12-11 2022-06-16 Maria Fardis Traitement de patients atteints de cancer par des therapies de lymphocytes infiltrant les tumeurs en combinaison avec des inhibiteurs de braf et/ou des inhibiteurs de mek
JP2024500403A (ja) 2020-12-17 2024-01-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球によるがんの治療
US20240299539A1 (en) 2020-12-17 2024-09-12 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022165260A1 (fr) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Procédés de fabrication de lymphocytes infiltrant les tumeurs modifiés et leur utilisation dans la thérapie cellulaire adoptive
WO2022198141A1 (fr) 2021-03-19 2022-09-22 Iovance Biotherapeutics, Inc. Procédés pour la multiplication des lymphocytes infiltrant les tumeurs (til) liés à la sélection de cd39/cd69 et inactivation de gènes dans les til
JP2024515189A (ja) 2021-04-19 2024-04-05 アイオバンス バイオセラピューティクス，インコーポレイテッド 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
WO2023004074A2 (fr) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Procédé de cryoconservation de fragments de tumeur solide
CA3226942A1 (fr) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Traitement de patients atteints d'un cancer avec des therapies de lymphocytes infiltrant les tumeurs en combinaison avec des inhibiteurs de kras
JP2024535002A (ja) 2021-09-09 2024-09-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１ ｔａｌｅｎノックダウンを使用したｔｉｌ製品を生成するためのプロセス
CA3235824A1 (fr) 2021-10-27 2023-05-04 Frederick G. Vogt Systemes et methodes pour coordonner la fabrication de cellules pour l'immunotherapie specifique d'un patient
US20250032618A1 (en) 2021-11-10 2025-01-30 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147488A1 (fr) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Compositions et procédés de lymphocytes infiltrant les tumeurs associés à la cytokine
WO2023196877A1 (fr) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Traitement de patients souffrant de cpnpc avec des thérapies lymphocytaires infiltrant les tumeurs
WO2023201369A1 (fr) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Processus d'expansion de til utilisant des combinaisons spécifiques de cytokine et/ou traitement akti
EP4522202A1 (fr) 2022-05-10 2025-03-19 Iovance Biotherapeutics, Inc. Traitement de patients atteints d'un cancer avec des thérapies lymphocytaires infiltrant les tumeurs en combinaison avec un agoniste d'il-15r
EP4565683A1 (fr) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Récepteurs de costimulation chimériques, récepteurs de chimiokines et leur utilisation dans des immunothérapies cellulaires
WO2024098024A1 (fr) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion de lymphocytes infiltrant les tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
EP4612277A1 (fr) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Procédés d'expansion de lymphocytes infiltrant les tumeurs (til) liés à la sélection de cd39/cd103
CN120584182A (zh) 2022-11-21 2025-09-02 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞扩增的二维过程及其疗法
WO2024112711A2 (fr) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Procédés d'évaluation de la puissance de prolifération de lymphocytes t génétiquement modifiés
WO2024118836A1 (fr) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs à étape rep raccourcie
WO2025101484A1 (fr) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Traitement de cancers endométriaux avec des thérapies lymphocytaires infiltrant les tumeurs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034970A1 (fr) * 1995-05-04 1996-11-07 United States Of America, Represented By The Secretary Of The Navy Procedes ameliores de transfection des lymphocytes t

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
WO1996017073A1 (fr) * 1994-11-29 1996-06-06 Takara Shuzo Co., Ltd. Procede pour la production de cellules transformees
US6692964B1 (en) * 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) * 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5885806A (en) 1995-11-28 1999-03-23 The Johns Hopkins University School Of Medicine Methods to prepare conditionally replicating viral vectors
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
JP4418536B2 (ja) * 1996-10-17 2010-02-17 オックスフォード バイオメディカ（ユーケー）リミテッド レトロウイルスベクター
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
TWI239352B (en) * 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
US6060317A (en) * 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
IL159637A0 (en) * 2001-07-10 2004-06-01 Johnson & Johnson Res Pty Ltd Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034970A1 (fr) * 1995-05-04 1996-11-07 United States Of America, Represented By The Secretary Of The Navy Procedes ameliores de transfection des lymphocytes t

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COSTELLO B. ET AL.: "GENE TRANSFER INTO STIMULATED AND UNSTIMULATED T LYMPHOCYTES BY HIV-1-DERIVED LENTIVIRAL VECTORS", GENE THERAPY, vol. 7, no. 7, April 2000 (2000-04-01), pages 596 - 604, XP001057677, ISSN: 0969-7128 *
DOUGLAS J. ET AL.: "EFFICIENT TRANSDUCTION OF HUMAN LYMPHOCYTES AND CD34+ CELLS VIA HUMAN IMMUNODEFICIENCY VIRUS-BASED GENE TRANSFER VECTORS", HUMAN GENE THERAPY, vol. 10, no. 6, 10 April 1999 (1999-04-10), pages 935 - 945, XP000891430, ISSN: 1043-0342 *
MOVASSAGH M. ET AL.: "HIGH LEVEL OF RETROVIRUS-MEDIATED GENE TRANSFER INTO DENDRITIC CELLS DERIVED FROM CORD BLOOD AND MOBILIZED PERIPHERAL BLOOD CD34+ CELLS", HUMAN GENE THERAPY, vol. 10, no. 2, 20 January 1999 (1999-01-20), pages 175 - 187, XP000960663, ISSN: 1043-0342 *
NALDINI L. ET AL.: "IN VIVO GENE DELIVERY AND STABLE TRANSDUCTION OF NONDIVIDING CELLS BY A LENTIVIRAL VECTOR", SCIENCE, vol. 272, 12 April 1996 (1996-04-12), pages 263 - 267, XP000583652 *
QUINN E. R. ET AL.: "T CELL ACTIVATION MODULATES RETROVIRUS-MEDIATED GENE EXPRESSION", HUMAN GENE THERAPY, vol. 9, no. 10, 1 July 1998 (1998-07-01), pages 1457 - 1467, XP001057661, ISSN: 1043-0342 *
UCHIDA N. ET AL.: "HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 20, 29 September 1998 (1998-09-29), pages 11939 - 11944, XP002215385, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
RU2280074C2 (ru) 2006-07-20
RU2003108736A (ru) 2005-02-10
CZ2003569A3 (cs) 2003-11-12
NZ524642A (en) 2007-01-26
US20040062756A1 (en) 2004-04-01
JP2004528806A (ja) 2004-09-24
US6627442B1 (en) 2003-09-30
CN1531596A (zh) 2004-09-22
NO20030901L (no) 2003-04-28
WO2002018609A2 (fr) 2002-03-07
NO20030901D0 (no) 2003-02-26
CN100443593C (zh) 2008-12-17
EP2031069A1 (fr) 2009-03-04
WO2002018609A9 (fr) 2003-08-14
MXPA03001758A (es) 2004-11-01
KR20030074592A (ko) 2003-09-19
EP1315823A2 (fr) 2003-06-04
IL154599A0 (en) 2003-09-17
CA2421063A1 (fr) 2002-03-07
AU8694701A (en) 2002-03-13
CA2421063C (fr) 2014-05-27
BR0113619A (pt) 2004-04-06
AU2001286947B2 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
WO2002018609A3 (fr) Methodes de transduction cellulaire stable a l'aide de vecteurs viraux
SI1257648T1 (sl) Antagonistiäśni selektivni vezavni agensi za osteoprotegerin vezavni protein
WO2001075087A3 (fr) Variantes de lasubtilisine
WO2005056807A3 (fr) Vecteur viral associe aux adenovirus bovins et leurs utilisations
WO2001070276A3 (fr) Vecteur aav5 de transduction de cellules cerebrales et pulmonaires
WO2005017101A3 (fr) Virus aviaire adenoassocie (aaav) et ses utilisations
WO2007072056A3 (fr) Vecteurs
WO2002046429A3 (fr) Polypeptides possedant une activite glucoamylase et acides nucleiques codant pour
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
WO2002008285A3 (fr) Molecules il-17 et leurs utilisations
WO2002006457A3 (fr) Genes de lipase
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
AU7381098A (en) Polypeptides having prolyl pipeptidyl aminopeptidase activity and nucleic acids encoding same
WO2005034733A3 (fr) Techniques et compositions pour le diagnostic et le traitement de la leucemie lymphocytaire chronique des cellules beta
WO2002014485A3 (fr) Nouveau gene kallikreine
WO2004007664A3 (fr) Vecteurs d'acides nucleiques
WO2000053776A3 (fr) Nouveaux genes humains du type kallikreine
BR0213774A (pt) Molécula de ácido nucleio isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
WO2002010393A3 (fr) Molecules d'acide nucleique isolees codant pour des facteurs inductibles derives de lymphocytes t, ou interleukines-21, proteines codees et leur utilisation
WO2002036627A3 (fr) Interferons, utilisations et compositions associees
WO2001098469A3 (fr) Polypeptides presentant une activite de la peroxydase et acides nucleiques codant pour ces polypeptides
WO2003052067A3 (fr) Transfection d'organelle induite par un vecteur
WO2005002511A3 (fr) Anticorps recombines, compositions et leurs methodes de fabrication et d'utilisation
WO2002006508A3 (fr) Cgtase et sequence d'adn codant celle-ci
BR0213773A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 154599

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2003-569

Country of ref document: CZ

Ref document number: 2421063

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001758

Country of ref document: MX

Ref document number: 1020037002964

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002522515

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 524642

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001286947

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001966434

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2003108736

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 018177255

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001966434

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11

WWP Wipo information: published in national office

Ref document number: 1020037002964

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-569

Country of ref document: CZ